seeking

RTICBM-189 是可透过血脑屏障的大麻素 1 型受体变构调节剂，在 Ca2+动员试验中pIC50为 7.54，对 hCB1和 mCB1的 pIC50分别为 5.29 和 6.25。

MFZ 10-7 是 mGluR5 的负变构调节剂。

BP 897 hydrochloride 是有效的部分多巴胺 D3受体激动剂和弱 D2受体拮抗剂，在多巴胺 D3 受体 (Ki=0.92 nM) 上显示出高亲和力，而在 D2 受体上显示出 70 倍的低亲和力 (Ki=61 nM)。它表现出对可卡因寻求行为的选择性抑制。

Ro60-0175 是 5- 羟色胺 2B (5-HT2B) 和 5- 羟色胺 2C (5-HT2C) 血清素受体亚型的选择性激动剂，常用富马酸盐形式。 它具有 5- 羟色胺 2B 受体激动剂和 5- 羟色胺 2C 受体激动剂的作用。

Tabernanthalog (TBG) 是一种5-HT2A 激动剂。在啮齿类动物中，Tabernanthalog 已被发现可促进结构神经可塑性并产生抗抑郁作用。

Opipramol (Ensidon) 是一种具有抗抑郁活性的化合物，可在大鼠自我给药模型中减弱了可卡因的寻求行为。Opipramol 是 sigma (σ) 受体激动剂，具有抗焦虑活性，可用于研究神经系统疾病。

PF-5006739 is an effective and selective inhibitor of CK1δ ε (IC50s: 3.9 nM and 17.0 nM, respectively). PF-5006739 is a potential therapeutic agent for a range of psychiatric disorders with low nanomolar in vitro potency for CK1δ ε and high kinome selecti

RTI-51可显著提高运动活性，可能作为治疗可卡因使用的化合物。RTI-51具有高效、选择性强且持久的替代作用，可减少寻药行为。

PF-4363467 是多巴胺D3 D2受体拮抗剂，具有减弱阿片类药物寻求行为的效果，同时避免了D2受体的常见副作用。它对D3R的 Ki值为3.1 nM，而对D2R的 Ki值则为692 nM。

Bifeprunox is a partial dopamine and serotonin agonist potentially for the treatment of schizophrenia. Bifeprunox suppresses in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation. Bifeprunox influences nicotine-seek

ABD459 is a neutral antagonist of the central cannabinoid 1 (CB1) receptor (Ki = 8.6 nM). It inhibits food consumption in nonfasted mice without affecting motor activity. ABD459 reduces active food seeking for 5-6 hours after treatment, with no rebound after washout. ABD459 also diminishes rapid eye movement (REM) sleep, with no alterations of wakefulness or non-REM sleep.

AT-1001 is an α3β4 nAChR partial agonist. AT-1001 attenuates stress-induced reinstatement of nicotine seeking in a rat model of relapse and induces minimal withdrawal in dependent rats. AT-1001 also potently and reversibly blocks epibatidine-induced inward currents in HEK cells transfected with α3β4 nAChR. Importantly, AT-1001 potently and dose-dependently blocks nicotine self-administration in rats, without affecting food responding. When tested in a nucleus accumbens (NAcs) synaptosomal preparation, AT-1001 inhibits nicotine-induced [³H]dopamine release poorly and at significantly higher concentrations compared with mecamylamine and conotoxin MII.

AZD-8418 is an mGlu2 receptor positive allosteric modulators that attenuates nicotine-taking and nicotine-seeking behavior. Acute treatment with AZD8418 (0.37, 1.12, 3.73, 7.46, and 14.92 mg kg) and AZD8529 (1.75, 5.83, 17.5, and 58.3 mg kg) deceased nicotine self-administration and had no effect on food-maintained responding. Chronic treatment with AZD8418 attenuated nicotine self-administration, but tolerance to this effect developed quickly. The inhibition of nicotine self-administration by chronic AZD8529 administration persisted throughout the 14 days of treatment. Chronic treatment with either PAMs inhibited food self-administration. AZD8418 (acute) and AZD8529 (acute and subchronic) blocked cue-induced reinstatement of nicotine- and food-seeking behavior.

[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (DiMe-C7) 是一种 Substance P 类似物，在大鼠大脑中对神经激肽 1 受体 (NK1R) 的作用与 Substance P 大致相等，但作用时间大大延长。[Glp5,(Me)Phe8,Sar9] Substance P (5-11) 能选择性地激活大鼠大脑间脑和中脑皮层的多巴胺代谢。[Glp5,(Me)Phe8,Sar9] Substance P (5-11) 还可增加大鼠运动活性，诱导成瘾剂寻求行为的恢复。

Myr-Tat-CBD3是一种抑制N型电压门控钙通道Cav2.2与collapsin response mediator protein 2 (CRMP2)之间的蛋白-蛋白相互作用的抑制剂。在10 µM的浓度下，该化合物能够约81%地抑制Cav2.2-CRMP2相互作用，并在大鼠初级背根神经节(DRG)神经元中抑制钾诱导的钙流入（IC50约为2.8 µM）。在20 µM的浓度下，Myr-Tat-CBD3能抑制钙电流，但不影响钠电流，在初级DRG神经元中表现出这种特性。经过脊髓内给药，myr-Tat-CBD3（20 µg/5 µl）能够防止大鼠脚掌撤回潜伏期因carrageenan注射而减少。此外，Myr-Tat-CBD3减少大鼠因线索引起的寻求可卡因行为的复发。

SB 206553是一种5-HT2C反向激动剂，可减弱大鼠对甲基苯丙胺 (Methamphetamine) 的依赖。SB 206553 对表达人重组5-HT2受体的HEK-293或CHO-K1细胞中的5-HT2受体配体具有活性，pKi值分别为5.6 nM (5-HT2A)、7.7 nM (5-HT2B) 和7.8 nM (5-HT2C)。SB 206553 可用于精神兴奋剂滥用障碍的研究。

KK-92A为穿透血脑屏障的GABAB阳性异构调节剂,能够抑制大鼠自主摄取酒精以及对酒精寻求的提示诱导复发行为.

BP 897 (2-Naphthalenecarboxamide, N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-) 是一种有效的部分多巴胺D3受体激动剂和弱D2受体拮抗剂，在多巴胺 D3 受体(Ki=0.92 nM) 上显示出高亲和力，而在 D2 受体上显示出 70 倍的低亲和力 (Ki=61 nM)。它表现出对可卡因寻求行为的选择性抑制。